tiprankstipranks
Cara Therapeutics (CARA)
NASDAQ:CARA
Holding CARA?
Track your performance easily

Cara Therapeutics (CARA) Income Statement

2,269 Followers

Cara Therapeutics Income Statement

Last quarter (Q3 2024), Cara Therapeutics's total revenue was $2.56M, a decrease of -63.13% from the same quarter last year. In Q3, Cara Therapeutics's net income was $-12.48M. See Cara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 10.55M$ 20.97M$ 41.87M$ 23.03M$ 135.08M$ 19.89M
Cost of Revenue
$ 4.69M$ 6.17M$ 7.27M---
Gross Profit
$ 5.86M$ 14.79M$ 34.60M$ 23.03M$ 135.08M$ 19.89M
Operating Expense
$ 92.41M$ 136.29M$ 122.14M$ 112.11M$ 129.70M$ 131.56M
Operating Income
$ -81.86M$ -109.15M$ -73.00M$ -89.08M$ 5.38M$ -111.68M
Net Non Operating Interest Income Expense
-$ 604.00K----
Other Income Expense
$ 1.00M$ 3.59M$ 2.06M$ -642.00K$ -2.33M$ -4.49M
Pretax Income
$ -84.23M$ -118.51M$ -85.47M$ -88.44M$ 7.72M$ -107.19M
Tax Provision
----$ -691.00K$ -816.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -91.22M$ -118.51M$ -85.47M$ -88.44M$ 8.41M$ -106.37M
Basic EPS
$ -1.68$ -2.19$ -1.59$ -1.74$ 0.18$ -2.49
Diluted EPS
$ -1.68$ -2.19$ -1.59$ -1.74$ 0.18$ -2.49
Basic Average Shares
$ 218.39M$ 54.15M$ 53.65M$ 50.72M$ 47.41M$ 42.67M
Diluted Average Shares
$ 218.39M$ 54.15M$ 53.65M$ 50.72M$ 47.92M$ 42.67M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 94.92M$ 142.46M$ 129.40M$ 112.11M$ 129.70M$ 131.56M
Net Income From Continuing And Discontinued Operation
$ -91.22M$ -118.51M$ -85.47M$ -88.44M$ 8.41M$ -106.37M
Normalized Income
$ -40.46M-----
Interest Expense
------
EBIT
$ -90.10M$ -117.91M$ -85.47M$ -88.44M$ 5.38M$ -107.19M
EBITDA
$ -88.85M$ -115.97M$ -85.23M$ -86.03M$ 5.59M$ -107.77M
Currency in USD

Cara Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis